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Abstract 
Tauopathies encompass a broad range of neurodegenerative diseases 
featuring extensive neuronal death and cognitive decline. However, research 
over the past thirty years has failed to significantly advance our understanding 
of how tau causes dementia, limiting the design of rational therapeutics. It has 
become evident that we need to expand our understanding of tau in physiology, 
in order to delineate how tau may contribute to pathology. This review will 
discuss recent evidence that has uncovered a novel aspect of tau function, 
based on its previously uncharacterised localisation to the synapse. Here, 
multiple streams of evidence support a critical role for synaptic tau in the 
regulation of synapse physiology. In particular, long-term depression, a form of 
synaptic weakening, is dependent on the presence of tau in hippocampal 
neurons. The regulation of tau by specific phosphorylation events downstream 
of GSK-3β activation appears to be integral to this signalling role. We will also 
describe how the regulation of synapse physiology by tau and its 
phosphorylation may inform our understanding of tauopathies and co-morbid 
diseases. This work should provide a platform for future tau biology research in 
addition to therapeutic design. 
Introduction 
Following the identification of the microtubule-associated protein (MAP) tau as a 
major component of neurofibrillary tangles (NFTs) in Alzheimer’s disease (AD) 
brains (Kosik and others 1986; Grundke-Iqbal and others 1986), numerous 
neurodegenerative disorders were soon classified as ‘tauopathies’, with tau as 
a seemingly integral component of neuronal pathology. Such diseases include 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-
17), progressive supranuclear palsy (PSP), Pick’s disease (PiD), corticobasal 
degeneration (CBD), among many others (Williams, 2006). The extent of 
tauopathy in AD appears to correlate strongly with the degree of cognitive and 
neuronal decline (Nelson and others, 2012), implicating tau as a causative 
factor for disease progression. Furthermore, mutations and polymorphisms to 
the tau gene (MAPT) are associated with approximately 5% of frontotemporal 
dementia cases and are established risk factors for PSP and CBD (Hutton and 
others, 1998; Goedert and others, 2012), suggesting that dysregulation of tau 
itself can indeed cause neurodegeneration. This notion is supported by 
experimental models of AD, in which the presence of tau is required, and can 
even be sufficient, for the manifestation of neurotoxicity and neurodegeneration 
(Fath and others, 2002; Rapoport and others, 2002; Roberson and others, 
2007; Ittner and others, 2010; Shipton and others, 2011; Zempel and others, 
2013; Kim and others, 2015). Reducing tau or limiting tau phosphorylation or 
aggregation in these models of disease has thus proved to be a highly effective 
method for reducing the pathological phenotype (Noble and others, 2005; 
Mocanu and others, 2008; Serenó and others, 2009; Sydow and others, 2011; 
Van der Jeugd and others, 2012; Zempel and others, 2013; Kim and others, 
2015). Consequently, an interest in developing tau-based therapeutics for AD 
patients has been awakened, with a particular focus on tau aggregation 
inhibitors, tau kinase inhibitors, and microtubule-stabilizing drugs. However, with 
these current approaches having shown poor or modest efficacy in clinical and 
preclinical trials, and alternative immunotherapy approaches still in their 
developmental infancy, a truly effective tau-based therapy seems like a distant 
reality (Anand and Sabbagh, 2015; Mably and others, 2015; Pedersen and 
Sigurdsson, 2015). 
It seems that despite the conspicuous link between tau and neurodegeneration, 
our understanding of the pathogenic effects of tau has failed to significantly 
evolve over recent years and this could ultimately limit the design of rational 
therapeutics. Overcoming this issue clearly requires an advanced 
understanding beyond existing hypotheses of how tau affects neuronal biology. 
It has been suggested that disturbances to the physiological functions of tau 
could be integral to the triggering of disease processes (Morris and others, 
2011). Therefore, our current lack of understanding of the relevance of tau to 
these disease phenotypes likely stems from the shadow of an existing dogma 
regarding the precise function of tau at a physiological level. Until recently, our 
knowledge in this regard has remained mostly limited to the role of tau in the 
establishment of neuronal polarity and axonal elongation, via its microtubule 
stabilizing capacity (Cáceres and Kosik, 1990; Esmaeli-Azad and others, 1994). 
In contrast, very little has been elucidated with regards to the role of tau in 
mature neurons, aside from its influence over the axonal transport of protein 
cargoes through effects upon microtubule-based motor proteins (Dixit and 
others, 2008). However, failures to observe overt neuronal and behavioural 
phenotypes in tau knockout mice cast doubt over the absolute physiological 
significance of these tau roles to neuronal and brain function (Morris and others, 
2011; Ke and others, 2012). With all of this in mind, it is now important to 
consider recent findings that have begun to uncover a novel role for tau in 
neuronal physiology, revealing a previously uncharacterised synaptic 
localization for tau where it acts to regulate synaptic function and plasticity. This 
review will highlight the evidence collected so far in this regard, and will discuss 
its implications for brain function and how this could contribute to further 
understanding of pathological processes and therapeutic advances in 
tauopathies. 
Axonal vs. dendritic tau: all about location? 
The canonical understanding of tau is that of an axonally segregated protein, 
whereby it acts to control neurite outgrowth and maintain neuronal polarity, 
primarily through its effects upon microtubule dynamics (Binder and others, 
1985; Hirokawa and others, 1988; Cáceres and Kosik, 1990). It had generally 
been considered to be absent from dendrites apart from in developing neurons 
(Kosik and Finch, 1987) or under pathological conditions (Kowall and Kosik, 
1987). However, a number of new observations are beginning to dispel this 
ideology and have led to the premise that tau is also located in dendrites as well 
as in pre- and post-synaptic structures of healthy neurons. As can be seen in 
Table 1, overwhelming evidence via numerous methodological approaches now 
supports this premise.  
It is not entirely clear why the dendritic localization of tau has only recently 
come to be appreciated. Epitope masking by different phosphorylation 
tendencies or protein-protein interactions of tau seems to have limited previous 
analysis of tau distribution (Binder and others, 1985). Indeed, the same 
antibody that failed to detect dendritic tau under normal conditions, readily 
detects tau in the somatodendritic domain following the removal of tau 
phosphorylation (Papasozomenos and Binder, 1987). This finding, and others 
(Tashiro and others, 1997), suggests that tau proteins exhibit subcellular 
compartmentalization based upon phosphorylation profile, possibly a result of a 
presence of a cellular gradient of tau kinase activity (Mandell and Banker, 
1996). It has now also been noted that different tau isoforms (see Box 1) 
display distinct subcellular localisation patterns, with 1N and 2N, but not 0N 
isoforms present in the dendrites, and an absence of 1N tau in axons (Liu and 
Götz, 2013). This evidence further supports the case for a differential 
distribution of tau-isoform populations between the axonal and dendritic 
compartments, in terms of both structure and phosphorylation, which may 
ultimately pertain to distinct functional roles. 
Observations from control human brains revealed that 70% of post-synaptic 
structures, which decorate dendritic branches, immunostained positive for tau 
(Tai and others, 2012). This makes it all the more remarkable that tau can only 
recently be said to have become generally accepted as a post-synaptic 
molecule (see Table 1). A possible explanation for this apparent delayed 
characterisation of tau as a post-synaptic protein may be its potentially short-
lived presence within these dendritic microdomains. Indeed, some evidence 
suggests that tau enters dendritic spines only transiently and in a regulated 
manner (Frandemiche and others, 2014). Such a transient and regulated 
presence may reflect fleeting microtubule invasion events carrying tau into and 
out of spines (Hu and others, 2008; Jaworski and others, 2009), although this 
possibility has yet to be proven or disproven. 
Regardless, the presence of tau in dendritic and synaptic compartments opens 
up a new and compelling chapter in tau biology, one that is laden with questions 
that must now be answered. For instance, Mandelkow and colleagues have 
previously provided evidence for the existence of a diffusion barrier that 
prevents tau from entering the somatodendritic compartment of mature neurons 
(Li and others, 2011). If true, this begs the question as to how tau can come to 
be located in these distinct cellular domains. This diffusion barrier is reported to 
be ineffective at sorting phosphorylated tau, or tau detached from microtubules 
(Li and others, 2011), lending weight once again to the notion that tau in the 
somatodendritic domain may have a distinct phosphorylation and functional 
profile to that of axonal tau. The observation that tau mRNA is also found in 
dendrites and dendritic spines (Malmqvist and others, 2014) opens up the 
possibility that local translation could provide the source of dendritic tau, 
mitigating the effects of any axonal barrier to protein diffusion. Alternatively, 
local trans-synaptic uptake of tau protein from the extracellular space, following 
its activity dependent release from pre-synaptic terminals remains a viable 
possibility (Pooler and others, 2013; Yamada and others, 2014; Sokolow and 
others, 2015). Such trans-synaptic spreading of tau could thus be hijacked in 
disease states, facilitating the propagation of tau pathology between 
interconnected brain regions (Clavaguera and others, 2009; de Calignon and 
others, 2012; Liu and others, 2012; Krüger and Mandelkow, 2015).   
Despite these unresolved issues, the true questions posed by this expanding 
pool of evidence for dendritic and post-synaptic tau relate to the physiological 
and functional significance of these findings. 
Tau regulation of synaptic function 
A number of circumstantial findings indicate that tau itself can regulate synaptic 
function. For example, tau can directly or indirectly modulate the signalling of 
synaptic receptors such as muscarinic acetylcholine receptors (mAChRs) and 
N-methyl-D-aspartate receptors (NMDARs) (Gómez-Ramos and others, 2009; 
Ittner and others, 2010). This is important given how pivotal these receptors are 
in normal physiological function of the synapse and their roles in cognition 
(Wess and others, 2007; Paoletti and others, 2013). Tau is also a substrate of 
glycogen synthase kinase-3β (GSK-3β) and p38 mitogen-activated protein 
kinase (p38MAPK) (Mandelkow and others, 1992; Goedert and others, 1997), 
enzymes found in the postsynaptic compartment that are involved in the 
regulation synaptic function, specifically long-term synaptic plasticity (Rush and 
others, 2002; Peineau and others, 2007). Interestingly, modulators of synaptic 
function, such as brain-derived neurotrophic factor (BDNF) and amyloid-β, fail 
to elicit their synaptic effects in neurons lacking tau (Shipton and others, 2011; 
Chen and others, 2012). Together, these findings strongly suggest that 
processes that modulate synaptic efficacy are dependent upon the presence of 
intracellular tau. However, until quite recently, no studies had directly tested the 
hypothesis that tau itself could be an important regulator of synaptic plasticity. 
In order to delineate a possible function of tau at the synapse, Kimura and 
colleagues studied neuronal function in the hippocampus of tau knockout mice. 
This brain region has been extensively used to study synaptic plasticity events, 
such as long-term potentiation (LTP) and long-term depression (LTD) at CA3-
CA1 synapses in particular (Andersen and others, 2007). In vivo and ex vivo 
electrophysiological recordings revealed a selective deficit in LTD, but not LTP, 
from the brains of mice with a homozygous or heterozygous tau deletion, but 
not from their wild-type counterparts (Kimura and others, 2014). Corroborating 
these findings, acute suppression of tau with tau-shRNA prevented the 
expression of LTD, and not LTP, in neurons from organotypic cultured 
hippocampal slices (Kimura and others, 2014; Regan and others, 2015). An 
important aspect of this in vitro study was the acute and sparse ablation of tau, 
largely restricted to CA1 neurons of the hippocampal slice. These factors 
eliminated any potential confounding developmental effects associated with tau 
knockout mice and ensured that LTD deficits could not be attributed to 
alterations of pre-synaptic afferents from the CA3 region, thus implicating post-
synaptic tau as the locus for LTD signalling. Replacing the silenced 
endogenous rat tau with human tau effectively restored the ability of these 
neurons to exhibit LTD, clearly demonstrating a specific requirement for tau 
protein in this form of synaptic plasticity (Kimura and others, 2014). The 
absence of any observable LTP deficit is consistent with one study that has 
shown normal LTP in tau knockout mice (Shipton and others, 2011) but 
contrasted with recent findings from another research group, who showed 
normal LTD and impaired LTP in the hippocampus of tau knockout mice 
(Ahmed and others, 2014). Furthermore, a recent study showed that LTD was 
readily inducible across mossy fiber (mf-LTD) synapses in tau knockout mice 
(Decker and others, 2015), raising the interesting question as to how to explain 
these opposing results. The answer likely stems from features of the different 
experimental models in terms of the age of the hippocampal slices and the 
induction protocols used for plasticity (Kemp and others, 2000; Ahmed and 
others, 2011), and/or reflects a specialisation of tau function at specific 
hippocampal synapse circuits depending on the locus or mechanisms of 
synaptic plasticity (e.g., tau-independent mf-LTD is expressed pre-synaptically 
(Kobayashi and others, 1996) whereas tau-dependent LTD at CA3-CA1 
synapses is generally regarded as post-synaptic (Collingridge and others, 
2010)). Therefore, it is undoubtedly important to probe further into a possible 
age-dependent and synapse-specific involvement of tau in mechanisms of 
synaptic plasticity induction, which could also provide further understanding into 
why certain forms of tau lead to neurotoxicity in the matured and/or aged brain. 
Together, these studies have unveiled a novel aspect to tau function, one that 
pertains to the regulation of synapses and their plasticity. Given the explicitly 
demonstrated role of synaptic plasticity processes in memory and recall (Nabavi 
and others, 2014) it is no surprise that behavioural studies in tau knockout mice 
show that this deficit in hippocampal LTD correlates with impaired memory 
performance, in particular hippocampus-dependent spatial reversal learning 
(Regan and others, 2015) (see Box 2). Thus, unlike previous functions 
attributed to tau, its role in synaptic regulation does not appear to be redundant 
or functionally compensated in tau knockout mice, underscoring the 
physiological significance of synaptic tau.   
A major remaining challenge is to resolve the capacity in which tau is involved 
in synaptic plasticity mechanisms within the post-synaptic domain. Our recent 
study showed that an interaction between protein interacting with C kinase 1 
(PICK1) and the GluA2 subunit of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) is impaired during LTD induction 
in tau knockout mice (Regan and others, 2015). Given the importance of this 
protein interaction for activity-driven AMPAR endocytosis and hippocampal LTD 
(Hanley and Henley, 2005; Citri and others, 2010), this is likely to reflect a 
mechanistic readout of the impaired LTD in tau knockout mice. Recent work 
using a transfected cell line has now shown that the presence of tau 
significantly enhances the GluA2-PICK1 interaction, supporting an important 
role for tau in regulating the association between these two proteins (Yagishita 
and others, 2015). However, the way in which tau might regulate this AMPAR 
endocytosis mechanism is not known and requires further investigation. 
Furthermore, tau can also bind to variety of other proteins that are known to be 
involved in the regulation of synaptic AMPARs (Reynolds and others, 2008; Liu 
and others, 2012), making it clear that tau has the potential to affect a number 
of different signal transduction cascades that pertain to the trafficking of 
AMPARs and thus the regulation of synaptic function. 
The phosphorylation signature of tau 
Alternative splicing and an array of post-translational modifications (PTMs) 
converge to make tau an incredibly heterogeneous species of protein (Larcher 
and others, 1992; Morris and others, 2015). Phosphorylation is undoubtedly the 
best-studied form of tau PTM, primarily a result of its indubitable links with tau 
aggregation and AD pathology (Goedert and others, 1992; Morishima-
Kawashima and others, 1995). However, tau is also highly phosphorylated in 
the absence of neurotoxicity, such as in the fetal brain, during hibernation, and 
to a lesser extent in the adult brain (Matsuo and others, 1994; Arendt and 
others, 2003; Yu and others, 2009). Tau phosphorylation is therefore not simply 
a pathological event, but clearly serves to regulate tau in a physiological sense. 
Little has been elucidated in this regard however; phosphorylation is known to 
affect the interaction of tau with microtubules and other binding partners 
(Biernat and others, 1993; Reynolds and others, 2008; Usardi and others, 
2011), but the actual physiological consequences of these effects are not 
evident.   
As alluded to above, tau species within distinct subcellular domains appear to 
be characterized by distinct ‘signatures’ of protein phosphorylation (Mandell and 
Banker, 1996; Tashiro and others, 1997). Indeed, a recent study has shown 
that tau within the post-synaptic density is most prominently doubly 
phosphorylated between resides 386 – 404 (Morris and others, 2015). But how 
can we relate these distinct phosphorylation signatures to the functional output 
of tau? Given the extremely labile nature of tau phosphorylation, this question 
remains fundamentally difficult to answer, but a number of recent insights are 
beginning to show clear phosphorylation-function relationships for tau, 
specifically at the synapse. 
Much of this knowledge has been ascertained through biochemical analysis of 
tau with phosphorylation residue-specific antibodies, followed by the analysis of 
mutant tau proteins with mutations preventing phosphorylation at those specific 
residues. For example, Frandemiche and colleagues found that chemically 
induced synaptic activity in cultured neurons resulted in increased tau 
phosphorylation at threonine 205, and this was associated with the 
translocation of tau from the dendrite to the synapse. Expressing a mutant form 
of tau, unable to be phosphorylated at threonine 205, appeared to compromise 
the stability of synaptically-translocated tau following the same synaptic 
activation paradigm (Frandemiche and others, 2014). Intriguingly, the same 
study found a similar synaptic translocation was induced by treatment of the 
neurons with amyloid-β, but this was associated with the phosphorylation of tau 
at serine 404. Thus, although both phosphorylation events appear to relate to 
synaptic translocation, the signature of tau phosphorylation seems to differ 
depending on the stimulus. 
Our group have shown that electrically driven synaptic activity elicits an 
increase in tau phosphorylation at serine residues 396 and 404, with no change 
in phosphorylation at serine 202 and threonine 205 residues (Kimura and 
others, 2014; Regan and others, 2015). This finding differs somewhat from the 
previously described study. While differences in the experimental substrate 
could be responsible, e.g. cultured neurons vs. hippocampal slices, an 
intriguing possibility is that differing forms of synaptic activity evoke differing 
signatures of tau phosphorylation. Specifically, threonine 205 phosphorylation 
was evoked by synaptic activity that induces LTP-like synaptic changes 
(Frandemiche and others, 2014), whereas serine 396 and 404 phosphorylation 
was evoked by an LTD-inducing stimulus (Kimura and others, 2014; Regan and 
others, 2015). Inhibitors of NMDARs and GSK-3β blocked this specific change 
in tau phosphorylation, and prevented the interaction of PICK1 with GluA2. 
Given the importance of NMDARs and GSK-3β to hippocampal LTD (Dudek 
and Bear 1992; Mulkey and Malenka 1992; Peineau and others, 2007; Peineau 
and others, 2009), these findings affirm the relevance of tau phosphorylation to 
LTD, and suggest that tau is probably a substrate for GSK-3β in an LTD 
signalling cascade downstream of NMDAR activation. The expression of mutant 
forms of tau demonstrated that tau phosphorylation, specifically at serine 396, is 
fundamentally required for LTD and has no effect on LTP (Regan and others, 
2015). This finding was unique in highlighting a distinct phosphorylation-to-
function relationship at just a single residue of tau. Therefore, it appears that 
phosphorylation of tau at serine 396 is an integral event in a GSK-3β signalling 
pathway that mediates synaptic weakening (Figure 1).  
Together, these findings demand further investigation into other 
phosphorylation signatures associated with and required for synaptic function. 
Similarly, the mechanisms by which tau phosphorylation can regulate synaptic 
function ought to be examined. One study suggests that phosphorylation of tau 
reduces the association of tau and Fyn with the post-synaptic density protein 
PSD-95 and the NMDAR subunit GluN2B (Mondragón-Rodríguez and others, 
2012). This supports a previous study informing that tau regulates the 
association of Fyn with NMDARs (Ittner and others, 2010), and suggests that 
tau phosphorylation may thus modulate NMDAR signalling via reduced GluN2B 
phosphorylation by Fyn. Data is presented to suggest that phosphorylation of 
tau at threonine 231 might be a critical regulator of this post-synaptic protein 
interaction (Mondragón-Rodríguez and others, 2012). Marrying this finding with 
the other observations of synaptically evoked tau phosphorylation signatures 
will be required to generate the complete picture of the physiological 
relationship between tau phosphorylation and function at the synapse. 
Finally, it will be important to consider the relevance of other tau PTMs when 
considering the synaptic function of tau. A recent paper described the array of 
other physiological PTMs - including methylation, acetylation, ubiquitination and 
O-GlcNAc modification - that are found at tau residues in brain tissue from wild-
type mice (Morris and others, 2015). These modifications have been relatively 
poorly studied thus far, but are known to affect microtubule binding, tau 
aggregation and degradation among other things, as well as cross-talk with 
other PTMs (Morris and others, 2015). Additionally, little is known about the 
physiological effects of C-terminal cleavage of tau by caspase, which occurs 
following the activation of GSK-3β and site-specific tau phosphorylation events 
(Cho and Johnson, 2004; Ding and others, 2006; Mondragón-Rodríguez and 
others, 2008) and is associated with synaptic dysfunction and memory 
impairment (Kim and others, 2015; Zhao and others, 2015). This facet of tau 
regulation is particularly intriguing given the roles of both caspase and GSK-3β 
in LTD signalling (Peineau and others, 2009; Li and others, 2010). Resolving 
the relationship between these PTMs and tau function remains a clear and 
fundamental challenge to enhancing our understanding of tau pathophysiology.  
A pathological perspective for synaptic tau  
Tau pathology, which is evident in tauopathies such as AD, is generally 
characterised by three main hallmarks: (i) tau becomes hyperphosphorylated, 
with the levels of tau-associated phosphate roughly tripling in AD brains 
compared to healthy adult brains (Köpke and others, 1993), (ii) tau is re-
distributed to the somatodendritic regions of neurons (Grundke-Iqbal and 
others, 1986; Kowall and Kosik, 1987), and (iii) hyperphosphorylated and 
cleaved tau proteins fold into structures that form paired-helical filaments, which 
then aggregate to form insoluble intra-neuronal NFTs (Grundke-Iqbal and 
others, 1986; Kosik and others, 1986; Goedert and others, 1988). It is generally 
considered that (i) leads to (ii) and (iii) to bring about tau pathology. Although 
amyloid pathology precedes this tau pathology in AD patients, correlative 
studies have shown that it is the extent of tau pathology that closely mirrors, 
and appears to dictate the extent of, neuronal loss and cognitive decline 
(Nelson and others, 2012; Murray and others, 2015). However, it has now 
become evident that NFTs themselves are actually dissociated from the decline 
in neuronal and cognitive function, and are neither necessary nor sufficient for 
neurotoxicity (Guerrero-Muñoz and others, 2015), arguing against their use as 
therapeutic targets. In light of this, it is now necessary to elucidate precisely 
how the hyperphosphorylation of tau can evoke neurotoxicity or synaptic 
dysfunction. 
A long-standing debate concerns whether neurotoxicity is triggered by the 
generation of a pathological species of tau protein, or whether physiological 
functions of tau are somehow disrupted; a gain of function or a loss of function. 
Two recent studies fall either side of this debate: Song and colleagues show 
that rTg4510 AD-model mice accumulate pathological species of tau carrying 
multiple PTMs at an early stage of disease progression (Song and others, 
2015). In contrast, Morris and colleagues provide evidence that tau from hAPP 
AD-model mice has similar PTMs to physiological tau found in wild-type mice 
(Morris and others, 2015). Clearly the difference in AD models must be playing 
a significant role in this discrepancy; whilst the rTg4510 model mice 
overexpress P301L mutant forms of human tau, the hAPP mice overexpress 
mutant forms of hAPP but with no genetic modifications to tau. Thus, the hAPP 
mice arguably provide a better model of sporadic tauopathies, i.e. the majority 
of cases of AD, where no mutations to the MAPT gene are present and tau is 
simply regulated or dysregulated by external stimuli (i.e., as a result of elevated 
amyloid-β). If we are to consider this hAPP model reliable, therefore, then a 
reasonable conclusion from the latter study is that a pathological species of tau 
is unlikely to be responsible for triggering neuropathology in AD, suggesting that 
dysregulation of the physiological functions of tau is more relevant to disease 
onset (Morris and others, 2015). Moreover, this study suggests that tau 
hyperphosphorylation in diseased states should be defined by an increase in 
the proportion of tau molecules that are phosphorylated at given residues, 
rather than an increase in the number of phosphorylated residues on each tau 
molecule. To put it another way, hyperphosphorylated tau, at least in the early 
stages of disease progression, likely reflects exaggerated physiological 
modifications to tau proteins, rather than the occurrence of new 
‘unphysiological’ modifications.  
What could this mean for tau function? Given that AD is widely considered to be 
a synaptic disorder (Selkoe, 2002; Scheff and others, 2006) and that the 
synaptic deficits induced by amyloid-β critically depend upon the presence of 
tau (Rapoport and others, 2002; Roberson and others, 2007; Ittner and others, 
2010; Shipton and others, 2011; Zempel and others, 2013); a new perspective 
for the causality of neurodegeneration by tau can be gained from what is now 
known about the actual physiological function of tau at the synapse. For 
example, up-regulation of LTD signalling is considered to be central to aberrant 
synaptic elimination in AD (Li and others, 2010; Jo and others, 2011; Regan 
and others, 2014) and amyloid-β has been shown to facilitate LTD (Kim and 
others, 2001; Hsieh and others, 2006; Shankar and others, 2008; Cheng and 
others, 2009; Li and others, 2009). Now we know that tau is intrinsic to LTD, 
these findings raise the intriguing possibility that synaptic tau function is 
aberrantly regulated by amyloid-β to enhance LTD signalling. Indeed, amyloid-β 
induces changes to tau phosphorylation and synaptic translocation that are 
similar to that induced by synaptic activation paradigms (Mondragón-Rodríguez 
and others, 2012; Frandemiche and others, 2014), suggesting that physiological 
synaptic functions of tau are somehow ‘hijacked’ by amyloid-β. Furthermore, 
synaptic internalization of AMPARs, a classical LTD expression mechanism, is 
induced by amyloid-β in a manner that is dependent upon tau phosphorylation 
(Miller and others, 2014). Therefore, one can predict that the aberrant 
phosphorylation of tau following the amyloid-β driven activation of kinases such 
as GSK-3β (Lei and others, 2011), cyclin-dependent kinase 5 (Cdk5) (Zempel 
and others, 2010), MAPK (Ferreira and others, 1997) or AMP-activated protein 
kinase (AMPK) (Mairet-Coello and others, 2013) will lead to the aberrant 
upregulation of LTD signalling and synaptic weakening in AD. Of these, the 
principal tau kinase GSK-3β may prove to be especially pertinent, given that its 
involvement in a critical LTD signalling cascade is known to be facilitated by 
amyloid-β (Li and others, 2010; Jo and others, 2011). Here, caspase-3 
activation leads to the cleavage of Akt1 and removal of constitutive GSK-3β 
inhibition. A wealth of evidence supports that amyloid-β and associated 
neurotoxic insults, such as reactive oxygen species, can activate neuronal 
caspase-3 (Marín and others, 2000; Garwood and others, 2011; Narayan and 
others, 2014), indicating that this signalling pathway culminating in GSK-3β 
mediated phosphorylation of tau could be integral to the shift towards 
pathological synaptic weakening and synapse loss (Figure 2).  
In this context, it is particularly interesting to note that phosphorylation of tau at 
serine 396, which we now know to be critical for LTD (Regan and others, 2015), 
has been shown to be an early event in Alzheimer’s disease pathogenesis 
(Mondragón-Rodríguez and others, 2014) and that tau phosphorylated at serine 
396 has been shown to accumulate in the post-synaptic compartments of AD 
brains and other tauopathies at an early stage (Muntané and others, 2008; Tai 
et al., 2012). Once again, these findings suggest that early synaptic loss in 
neurodegenerative diseases such as AD could be mediated through the 
aberrant enhancement of a physiological tau phosphorylation signal at the 
synapse. 
Dementia co-morbidities: tau as the missing link? 
On a final note, it is worth considering evidence that tau hyperphosphorylation 
is a common response to many neuronal stressors, such as hypothermia, 
glucose deprivation (Yanagisawa and others, 1999; Planel and others, 2004), 
diabetes (Wang and others, 2014; Platt and others, 2015) and chronic stress 
(Sotiropoulos and others, 2011). These findings highlight an intriguing 
molecular crossover between neurodegenerative pathways and the effects of 
other changes to the biological environment that are considered to precipitate 
the onset of dementia. For example, chronic stress and diabetes are thought to 
contribute to a neurodegenerative phenotype, as evidence by their considerable 
co-morbidity in both patients and experimental models (Magariños and 
McEwen, 2000; Janson and others, 2004; Artola, 2008; Stranahan and others, 
2008; Srivareerat and others, 2009; Verdile and others, 2015). In particular, 
experimental models have shown that chronic exposure to stress hormone 
glucocorticoids facilitates LTD signalling (Kim and others, 1996; Xu and others, 
1997; Yang and others, 2004) and induces tau accumulation at the synapse, 
with a specific increase in serine-396-phosphorylated tau within the synaptic 
compartment (Pinheiro and others, 2015). Furthermore, a similar effect has 
been shown with the proBDNF valine 66 (Val66) isoform, which conveys an 
increased susceptibility to cognitive decline and AD in late life, as compared to 
its methionine 66 (Met66) isoform (Ventriglia and others, 2002; Harris and 
others, 2006; Voineskos and others, 2011). Treatment of brain slices with 
proBDNF Val66 facilitates LTD and this is mediated via the activation of GSK-
3β and associated with an increase in tau phosphorylation at serine 396/404 
(Kailainathan and others, 2016). Together, these findings indicate a 
convergence of external synapse weakening/death factors upon synaptic tau 
function that could potentially ‘prime’ a diseased brain state and promote the 
onset of dementia. 
Conclusion 
Recent work revealing the function and regulation of tau at the synapse has 
strayed beyond the existing dogmatic approach to tau research. Tau function is 
clearly far more diverse than has largely been considered, with tau taking on 
multiple roles within the neuron. It will be essential to incorporate this new level 
of understanding into designing rationale for therapeutic approaches aimed at 
tau, if we are to facilitate the development of efficacious treatments for 
tauopathies. 
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Figure Legends 
Figure 1. Putative model for the role of tau and tau phosphorylation during 
synaptic weakening. During basal conditions (left) tau is present in dendrites 
and dendritic spines, where it is most likely bound to microtubules and has low 
levels of phosphorylation (pTau). A synaptic weakening stimulus (right) triggers 
Ca2+ influx through NMDARs that activates signalling cascades involving the 
serine/threonine kinase GSK-3β. GSK-3β mediates the transient 
phosphorylation of tau at serine 396, which is a critical event for subsequent 
AMPAR internalization. Downstream effects of tau phosphorylation depend 
upon its specific interacting partners at the synapse, but may involve changes 
to microtubule stability and/or the regulation of NMDARs via Fyn trafficking, 
ultimately regulating the association of an AMPAR-PICK1 complex. 
Figure 2. Conceptual schematic illustrating synapse pathology in tauopathies. 
Neurotoxic pathogens such as amyloid-β aberrantly activate a synapse 
weakening CAG signalling cascade and simultaneously inhibit synapse 
strengthening pathways, together converging on the hyperphosphorylation of 
tau (pTau). pTau at the synapse drives excessive LTD signalling, resulting in a 
shift from the basal state towards pathological synapse loss and 
neurodegeneration. 
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Tau refers to a group of closely related proteins found primarily in the central nervous system (CNS). These proteins 
were initially identified when they co-purified with the microtubule subunit-forming protein tubulin (Weingarten and 
others, 1975) and were hence classified as microtubule-associated proteins (MAPs) that regulate microtubule 
stability (Drechsel and others, 1992). Human tau proteins are encoded by the MAPT gene (chromosome 17) 
containing 16 exons that, with the exception of exons 4a, 6 and 8, are all transcribed to generate the primary tau 
mRNA transcript. Exons -1 and 14 are not part of the final mRNA product, while exons 2, 3 and 10 are subject to 
alternative splicing (Andreadis and others, 1992). The primary structure of human CNS tau protein isoforms, which 
range from 352 to 441 amino acids in length, is thus determined by the presence or absence of mRNA elements 
encoded by these exons. All tau proteins contain at least three amino acid repeat regions towards the C-terminus 
that are considered to be the primary sites of interactions with microtubules. Together with a central proline-rich 
region and a C-terminal flanking region, these repeat sequences form the ‘microtubule-binding domain’ of tau. In 
some isoforms, this domain is extended by the inclusion of exon 10, which dictates the presence of a fourth 
microtubule-binding repeat region. In contrast, a stretch of ~ 120 amino acids constitutes a ‘projection domain’ at the 
N-terminal region of tau. This domain is modifiable by the inclusion of an amino acid sequence encoded by exon 2 
or by exons 2 and 3. Thus, tau protein isoforms are generally denoted by their combination of N-terminal inserts and 
C-terminal repeats, of which there are six possibilities; 0N3R, 0N4R, 1N3R, 1N4R, 2N3R and 2N4R (full-length) tau. 
Box 1. Tau protein isoforms
4 5 7 9 11-131 2 10
4 5 7 9 11-131 10
4 5 7 9 11-131 2 3
4 5 7 9 11-131 2
4 5 7 9 11-131
 
Table 1. Evidence for dendritic and synaptic tau in healthy neurons 
[1] Papasozomenos and Binder, 1987; [2] Tashiro and others, 1997; [3] Muntané and others, 
2008; [4] Ittner and others, 2010; [5] Hoover and others, 2010; [6] Tai and others, 2012; [7] 
Mondragón-Rodríguez and others; 2012 [8] Liu and Götz, 2013; [9] Perez-Nievas and others, 
2013; [10] Kimura and others, 2014; [11] Frandemiche and others, 2014; [12] Miller and others, 
2014; [13] Xia and others, 2015; [14] Pinheiro and others, 2015; [15] Morris and others, 2015; 
[16] Jadhav and others, 2015; [17] Zhao and others, 2015. Abbreviations: WT = wild-type; pTau 
= phosphorylated tau; hTau = human tau; cTau = cleaved tau; PSD = post-synaptic density; 
GFP = green fluorescent protein; FRAP = fluorescence recovery after photobleaching; GC = 
glucocorticoid; TG = transgenic 
Table 1:  Evidence for dendritic and synaptic tau in healthy neurons 
Ref. Method(s) Observation(s) 
[1] • Immunohistochemistry • Dendritic tau staining following removal of pTau 
[2] • Immunohistochemistry • pTau in soma/dendrites of rat cortical neurons 
[3] • Subcellular fractionation • Tau in human brain synaptic fractions 
[4] • Co-immunoprecipitation 
• PSD purification 
• Immunohistochemistry 
• Endogenous tau in dendrites and PSD fraction, and co-
precipitates with PSD-95 in WT mouse hippocampus 
[5] • Subcellular fractionation 
• Immunocytochemistry 
• WT hTau present in PSD fraction from TG mouse forebrain 
• GFP-hTau localises to spines in mouse primary neurons 
[6] • Synaptoneurosomes  
• PSD purification 
• Immunocytochemistry 
• Tau is present in 70% of postsynaptic sites and is present 
in a PSD-enriched fraction from control human brains 
[7] • Synaptosomes 
• Immunocytochemistry 
• Electron microscopy 
• Co-immunoprecipitation 
• Endogenous tau is present in dendrites and post-synaptic 
sites in rat hippocampal neurons, and co-precipitates with 
PSD-95 
[8] • Immunohistochemistry • 2N/1N tau staining in dendrites of mouse hippocampus 
[9] • Synaptoneurosomes • Tau present in the synaptic fractions of human brains  
[10] • Immunogold electron microscopy 
• Synaptosomes 
• Endogenous tau is present at pre- and post-synaptic sites 
of WT mouse hippocampal neurons  
[11] • Immunocytochemistry 
• FRAP 
• Subcellular fractionation 
• GFP-hTau colocalisation to dendritic spines of mouse 
cortical neurons; increased by synaptic activation 
• Endogenous mouse tau in PSD fraction of primary cortical 
neurons; increased by synaptic activation 
[12] • Immunocytochemistry • GFP-tagged hTau localised in a subset of dendritic spines 
of primary cultured hippocampal neurons from WT mice 
[13] • Immunocytochemistry 
• Synaptosomes 
• Endogenous tau localises to dendrites/spine heads of 
primary cultured hippocampal neurons from WT mice 
• pTau increased localisation to dendritic spines 
• Tau present in forebrain synaptosomal fractions 
[14] • Subcellular fractionation 
• Electron microscopy 
• Tau in dendrites and synaptic fraction of rat hippocampal 
neurons; altered by GC treatment 
[15] • Subcellular fractionation • Endogenous tau in the PSD fraction of WT mouse brain 
[16] • Synaptosomes • Endogenous tau in PSD fraction of rat neurons 
[17] • Immunocytochemistry 
• Synaptosomes 
• Endogenous cTau in dendrites of cultured neurons from 
WT rats and mice. 
• Endogenous tau and cTau in synaptosomal and PSD 
fractions from primary rat cortical neurons 
Studies have shown that tau KO mice have normal cognition in spatial learning tasks such as 
Y-maze, T-maze, and water maze tests (Morris and others, 2011). What then, is the underlying 
relevance of the finding that tau is required for LTD? Conceptually, LTD-like physiological synapse 
weakening is thought to contribute to information encoding and discrimination, and is considered to 
be a fundamental cellular mechanism in certain cognitive processes such as novelty discrimination 
and tasks requiring behavioural flexibility (Kemp and Manahan-Vaughan, 2007; Nicholls and others, 
2008). Accordingly, a behavioural task such as spatial reversal learning – the ability to forget one 
location and learn another within a specific context – is dependent on hippocampal LTD (Nicholls 
and others, 2008; Dong and others, 2013). Using the Barnes maze test to assay this form of learning, 
tau KO mice took significantly longer to adapt to the relocation of an escape hole, indicative of 
impaired reversal learning and behavioural flexibility (Regan and others, 2015). This finding is 
supportive of a notion that tau KO mice exhibit deficits in cognitive aspects that are specific to 
hippocampal LTD, and underscores the physiological importance for the role of tau at the synapse. 
It is likely that previous behavioural goal-oriented spatial learning tasks were not sensitive to subtle 
deficits in this particular form of hippocampal plasticity.
Box 2. Tau and cognition
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Low levels of pTau
Synapse weakening
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Amyloid-
(or other 
pathogens)
Synapse strengthening pathway
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(CAG Cascade)
Caspase GSK-3 
PI3K
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Synapse strengthening
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Akt1
